Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
20(S)-protopanaxadiol is a dammarane-type triterpenoid that serves as the aglycone (non-sugar) derivative of major ginsenosides found in plants such as Panax ginseng, Gynostemma pentaphyllum, and Aralia elata[1][7]. It is a metabolite of ginseng saponins and is formed by the deglycosylation of ginsenosides in the gut[8][9]. Preclinical studies have demonstrated that 20(S)-protopanaxadiol exhibits anticancer activity by inducing apoptosis in various tumor cells, including human endometrial cancer and colon cancer[4][5]. The anticancer effects are mediated through multiple pathways: activation of caspases (especially caspase-9), cleavage of poly(ADP-ribose) polymerase (PARP), inhibition of Akt activity, and suppression of NF-κB, JNK, and MAPK/ERK signaling[4][5]. In addition to its antitumor properties, 20(S)-protopanaxadiol has also been shown to prolong lifespan and enhance stress resistance in the model organism Caenorhabditis elegans via modulation of the insulin/IGF-1 signaling pathway[6]. As of current data, 20(S)-protopanaxadiol is not approved as a pharmaceutical drug for any indication and remains a subject of preclinical research. Its main relevance is as a bioactive natural product and a lead compound for drug discovery. **Molecular properties** - Molecular formula: C₃₀H₅₂O₃ - Molecular weight: 460.73 g/mol - Appearance: White solid - Melting point: 197–200 °C - Density: 1.036 g/cm³ - Solubility: Slightly soluble in chloroform, methanol, and pyridine[3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 20(S)-protopanaxadiol.